valsartan has been researched along with Blood Pressure, Low in 41 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (14.63) | 29.6817 |
| 2010's | 12 (29.27) | 24.3611 |
| 2020's | 23 (56.10) | 2.80 |
| Authors | Studies |
|---|---|
| Bedhomme, S; Bouchant, S; Boussageon, R; Bœuf-Gibot, S; Charuel, E; Menini, T; Pereira, B; Piñol-Domenech, N; Vaillant-Roussel, H | 1 |
| Berwanger, O; Braunwald, E; Cikes, M; Claggett, B; De Pasquale, CG; East, C; Fernandez, A; Gong, J; Granger, CB; Jering, K; Køber, L; Landmesser, U; Lefkowitz, M; Lewis, EF; Maggioni, AP; Mann, DL; McMurray, JJV; Mehran, R; Merkely, B; Petrie, MC; Petrov, I; Pfeffer, MA; Rouleau, JL; Schou, M; Senni, M; Sim, D; Solomon, SD; Steg, PG; Vaghaiwalla Mody, F; van der Meer, P; Zhou, Y | 1 |
| Chen, X; Feng, Y; Li, W; Liu, H | 1 |
| Cartailler, J; Cohen-Solal, A; Launay, JM; Lefèvre, G; Logeart, D; Michel, T; Nougué, H; Picard, F; Sadoune, M; Vodovar, N | 1 |
| Alemayehu, WG; Armstrong, PW; Butler, J; Edelmann, F; Ezekowitz, J; Hernandez, AF; Lam, CSP; McMullan, C; O'Connor, CM; Pieske, B; Ponikowski, P; Roessig, L; Senni, M; Sim, D; Voors, AA; Westerhout, CM | 1 |
| Chen, C; Fan, L; Li, J; Li, X; Lv, Q; Tian, D; Zuo, C | 1 |
| Butt, JH; Claggett, BL; de Boer, RA; Desai, AS; Docherty, KF; Hernandez, AF; Inzucchi, SE; Jering, KS; Jhund, PS; Kondo, T; Kosiborod, MN; Lam, CSP; Langkilde, AM; Martinez, FA; McMurray, JJV; Petersson, M; Shah, SJ; Solomon, SD; Vaduganathan, M; Wilderäng, U; Yang, M | 1 |
| Shaikh, AS; Xu, XD; Yang, HR; Zhou, BT | 1 |
| Ashraf, T; Balouch, IJ; Bashir, S; Bhatti, UH; Karim, M; Khan, MN; Moazzam, A; Naseeb, K; Rauf, R; Soomro, NA | 1 |
| Chen, R; Cheng, Y; Deng, P; Gao, LC; Li, CX; Li, FJ; Li, HL; Li, L; Long, HZ; Luo, HY; Peng, XY; Xu, SG; Zhou, ZW | 1 |
| Braunwald, E; Desai, AS; Hernandez, AF; Lepage, S; Mentz, RJ; Morrow, DA; Sarwat, S; Sharma, K; Solomon, SD; Starling, RC; Velazquez, EJ; Ward, JH; Williamson, KM; Zieroth, S | 1 |
| Ako, J; Eda, Y; Fujita, T; Iida, Y; Ikeda, Y; Ishii, S; Koitabashi, T; Nabeta, T; Oikawa, J; Takigami, Y; Yazaki, M | 1 |
| Ji, XP; Lin, ZW; Lyu, HX; Wu, AH | 1 |
| Anand, IS; Boytsov, SA; Claggett, B; Cleland, J; Comin-Colet, J; Desai, AS; Düngen, HD; Ge, J; Goncalvesova, E; Gong, J; Jhund, PS; Katova, T; Kerr Saraiva, JF; Lam, CSP; Lefkowitz, MP; Lelonek, M; Maggioni, AP; Martinez, F; McMurray, JJV; Merkely, B; Packer, M; Pfeffer, MA; Pieske, B; Redfield, MM; Rizkala, AR; Rouleau, JL; Senni, M; Shah, SJ; Shi, VC; Solomon, SD; van Veldhuisen, DJ; Zannad, F; Zhou, J; Zile, MR | 1 |
| Chang, HY; Yin, WH | 1 |
| Hryniewiecki, T; Kodziszewska, K; Kruszewski, M; Leszek, P; Pączek, L; Śmigielski, W; Sochanowicz, B | 1 |
| Berge, E; Julius, S; Kjeldsen, SE; Liestøl, K; Mancia, G; Mehlum, MH; Parati, G; Rothwell, PM; Weber, MA; Wyller, TB | 1 |
| Ambrosy, AP; Braunwald, E; Desvigne-Nickens, P; DeVore, AD; Gilotra, NA; Givertz, MM; Gorodeski, EZ; Greene, SJ; Gupta, D; Hernandez, AF; Lala, A; Lewis, GD; Mahr, C; Mann, DL; McNulty, SE; Mohammed, SF; Redfield, MM; Shah, P; Starling, RC; Vader, JM | 1 |
| Chen, YH; Lai, HC; Lee, WL; Liu, TJ | 1 |
| Elston, C; Gengler, B; Kester, J; Montepara, C; Rerick, L | 1 |
| Caldeira, D; Costa, J; David, C; Ferreira, JJ; Katerenchuk, V; Martins E Pereira, G; Pinto, FJ; S Duarte, G | 1 |
| Chen, C; Fang, C; Huang, Y; Ma, L; Zhang, Y; Zhou, H | 1 |
| Brar, S; D'Albo, N; Dani, SS; Dey, A; Ganatra, S; Kim, YS; Shah, S | 1 |
| Abdul-Aziz, AA; Adie, SK; Ketcham, SW; Konerman, MC; Thomas, MP | 1 |
| Aspromonte, N; De Maria, R; Di Lenarda, A; Di Tano, G; Frigerio, M; Gabrielli, D; Gulizia, MM; Iacoviello, M; Mortara, A; Murrone, A; Nardi, F; Oliva, F; Pontremoli, R; Scherillo, M; Senni, M; Urbinati, S | 1 |
| Adie, S; Bitar, A; Dorsch, M; Hanigan, S; Koelling, T; Pogue, K | 1 |
| Chang, HC; Chang, HY; Chen, CN; Chong, E; Feng, AN; Fong, MC; Hsueh, CW; Huang, KC; Lai, WT; Yin, WH | 1 |
| Chen, Q; Fang, Y; Li, S; Lv, S; Tian, X; Zhou, H | 1 |
| Jacob, MS; Sabe, MA; Taylor, DO | 1 |
| Anand, I; Andreka, P; Charney, A; Chen, F; Cosmi, F; Fischer, S; Galve, E; Gelev, V; Gogia, H; Gómez-Doblas, JJ; Majercak, I; Martinez-Selles, M; McIntyre, HF; McMurray, JJ; Nociar, J; Radomska, M; Reimund, B; Reyes, A; Sarkar, A; Senni, M; Shehova-Yankova, N; Sokolova, B; Volterrani, M; Wachter, R; Yilmaz, MB; Zilahi, Z | 1 |
| Akpek, M; Avcil, M; Kantekin, B; Kapçı, M; Yavaşoğlu, I | 1 |
| Cheng, J | 1 |
| Bruno, RM; Taddei, S | 1 |
| Böhm, M; Gong, J; Jhund, PS; Lefkowitz, MP; McMurray, JJV; Packer, M; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Young, R; Zile, MR | 1 |
| Ferguson, KL; Greller, HA; Hoffman, RS; Nelson, LS; Smith, SW | 1 |
| Bailey, J; Black, HR; Samuel, R; Zappe, D | 1 |
| Nabbi, R; Riess, ML; Woehlck, HJ | 1 |
| Jorde, UP | 1 |
| Carey, RM; de Gasparo, M; Siragy, HM | 1 |
| Carey, RM; Howell, NL; Jin, XH; Siragy, HM | 1 |
| Haddy, FJ | 1 |
6 review(s) available for valsartan and Blood Pressure, Low
| Article | Year |
|---|---|
Benefits and adverse effects of sacubitril/valsartan in patients with chronic heart failure: A systematic review and meta-analysis.
Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Heart Failure; Hospitalization; Humans; Hyperkalemia; Hypotension; Mortality; Renal Insufficiency; Risk Assessment; Stroke Volume; Valsartan | 2021 |
Efficacy and Safety of Sacubitril/Valsartan Compared With ACEI/ARB on Health-Related Quality of Life in Heart Failure Patients: A Meta-Analysis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Combinations; Heart Failure; Humans; Hypotension; Quality of Life; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Safety and tolerability of sacubitril-valsartan: a systematic review and meta-analysis.
Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Humans; Hypotension; Randomized Controlled Trials as Topic; Risk; Tetrazoles; Valsartan | 2021 |
Adverse Events of Sacubitril/Valsartan: A Meta-analysis of Randomized Controlled Trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Heart Failure; Humans; Hypotension; Male; Middle Aged; Neprilysin; Protease Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome; Valsartan; Young Adult | 2021 |
Five Years of Sacubitril/Valsartan-a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance.
Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hyperkalemia; Hypotension; Kidney Diseases; Pharmacovigilance; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2022 |
Valsartan: more than a decade of experience.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydrochlorothiazide; Hypertension; Hypotension; Meta-Analysis as Topic; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 2009 |
10 trial(s) available for valsartan and Blood Pressure, Low
| Article | Year |
|---|---|
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Female; Heart Failure; Hospitalization; Humans; Hypotension; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Ramipril; Stroke Volume; Valsartan; Ventricular Dysfunction, Left | 2021 |
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Heterocyclic Compounds, 2-Ring; Humans; Hyperkalemia; Hypotension; Pyrimidines; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left | 2022 |
Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction.
Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Female; Heart Failure; Humans; Hyperkalemia; Hypotension; Kidney Diseases; Male; Middle Aged; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left | 2023 |
Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypotension; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
Topics: Aged; Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypotension; Male; Middle Aged; Neprilysin; Quality of Life; Sex Factors; Single-Blind Method; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Blood Pressure-Lowering Profiles and Clinical Effects of Angiotensin Receptor Blockers Versus Calcium Channel Blockers.
Topics: Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blood Pressure Determination; Calcium Channel Blockers; Female; Heart Failure; Humans; Hypotension; Male; Middle Aged; Myocardial Infarction; Outcome and Process Assessment, Health Care; Risk Assessment; Stroke; Time; Valsartan | 2020 |
Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Betacoronavirus; Biphenyl Compounds; Cardiotonic Agents; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Early Termination of Clinical Trials; Glomerular Filtration Rate; Heart Failure; Heart Transplantation; Heart-Assist Devices; Hospitalization; Humans; Hypotension; Natriuretic Peptide, Brain; Pandemics; Peptide Fragments; Pneumonia, Viral; SARS-CoV-2; Stroke Volume; Tetrazoles; Valsartan | 2020 |
A new class of drugs for systolic heart failure: The PARADIGM-HF study.
Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular Diseases; Cough; Double-Blind Method; Drug Combinations; Enalapril; Female; Heart Failure, Systolic; Hospitalization; Humans; Hyperkalemia; Hypotension; Male; Middle Aged; Neprilysin; Renal Insufficiency; Tetrazoles; Valsartan | 2015 |
Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Female; Heart Failure; Humans; Hyperkalemia; Hypotension; Male; Middle Aged; Neprilysin; Renal Insufficiency; Tetrazoles; Treatment Outcome; Valsartan | 2016 |
Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Blood Pressure; Chronic Disease; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Enalapril; Female; Heart Failure; Hospitalization; Humans; Hypotension; Male; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2017 |
25 other study(ies) available for valsartan and Blood Pressure, Low
| Article | Year |
|---|---|
Low dose sacubitril/valsartan is effective and safe in hemodialysis patient with decompensated heart failure and hypotension: A case report.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Female; Heart Failure; Humans; Hypotension; Neprilysin; Renal Dialysis; Tetrazoles; Valsartan | 2022 |
proANP Metabolism Provides New Insights Into Sacubitril/Valsartan Mode of Action.
Topics: Aminobutyrates; Atrial Natriuretic Factor; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypotension; MicroRNAs; Neprilysin; Stroke Volume; Valsartan | 2022 |
Effectiveness and safety evaluation of sacubitril/valsartan in blood pressure control and clinical outcomes for elderly patients with heart failure and hypertension: A prospective cohort study.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Drug Combinations; Heart Failure; Humans; Hypertension; Hypotension; Prospective Studies; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2023 |
Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypotension; Male; Mineralocorticoid Receptor Antagonists; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Association between the NEP rs701109 polymorphism and the clinical efficacy and safety of sacubitril/valsartan in Chinese patients with heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; East Asian People; Heart Failure; Humans; Hypotension; Neprilysin; Polymorphism, Genetic; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2023 |
The efficacy and safety of sacubitril/valsartan in heart failure with reduced ejection fraction patients with hypotension.
Topics: Drug Combinations; Heart Failure; Humans; Hypotension; Stroke Volume; Tetrazoles; Valsartan | 2023 |
[Titration strategy of sacubitril/valsartan in patients with heart failure with reduced ejection fraction and hypotension].
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Drug Combinations; Heart Failure; Humans; Hypotension; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2023 |
Response to "Grey Areas and Open Questions in Neprilysin Inhibition".
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypotension; Neprilysin; Renal Insufficiency, Chronic; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Grey areas and open questions in neprilysin inhibition.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypotension; Neprilysin; Renal Insufficiency, Chronic; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Iatrogenic Takotsubo Cardiomyopathy Following Overdose Norepinephrine Administration During Percutaneous Coronary Intervention.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Bisoprolol; Coronary Restenosis; Creatine Kinase; Creatine Kinase, MB Form; Drug Overdose; Drug-Eluting Stents; Echocardiography; Humans; Hypotension; Iatrogenic Disease; Intra-Aortic Balloon Pumping; Intraoperative Complications; Male; Medication Errors; Middle Aged; Norepinephrine; Percutaneous Coronary Intervention; Recovery of Function; Shock, Cardiogenic; Stents; Stroke Volume; Takotsubo Cardiomyopathy; Troponin I; Valsartan; Vasoconstrictor Agents | 2020 |
Evaluation of Sacubitril/Valsartan Initiation in Outpatient Heart Failure Patients.
Topics: Aged; Ambulatory Care; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Female; Guideline Adherence; Heart Failure; Humans; Hypotension; Inappropriate Prescribing; Male; Middle Aged; Neprilysin; Outpatients; Practice Guidelines as Topic; Protease Inhibitors; Recovery of Function; Retrospective Studies; Time Factors; Treatment Outcome; Valsartan | 2021 |
Characteristics of Heart Failure Patients With or Without Hypotension When Transitioning From Nitroprusside to Sacubitril-Valsartan.
Topics: Adult; Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood Pressure; Coronary Care Units; Diuretics; Drug Combinations; Female; Heart Failure; Humans; Hypotension; Male; Middle Aged; Neprilysin; Nitroprusside; Protease Inhibitors; Retrospective Studies; Risk Factors; Treatment Outcome; Valsartan; Vasodilator Agents | 2021 |
[ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure].
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Comorbidity; Contraindications, Drug; Drug Combinations; Early Termination of Clinical Trials; Heart Failure; Humans; Hypotension; Monitoring, Physiologic; Multicenter Studies as Topic; Neprilysin; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Reproducibility of Results; Stroke Volume; Tetrazoles; Valsartan | 2018 |
Real-World Prevalence of Adverse Events After Initiating Sacubitril/Valsartan Compared With Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Systolic Heart Failure.
Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cohort Studies; Drug Combinations; Female; Glomerular Filtration Rate; Heart Failure, Systolic; Humans; Hyperkalemia; Hypotension; Male; Middle Aged; Retrospective Studies; Tetrazoles; Valsartan | 2019 |
Sacubitril/valsartan in heart failure with reduced ejection fraction patients: Real world experience on advanced chronic kidney disease, hypotension, and dose escalation.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Dose-Response Relationship, Drug; Drug Combinations; Female; Heart Failure; Hospitalization; Humans; Hypotension; Male; Middle Aged; Renal Insufficiency, Chronic; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2019 |
Opiorphin increases blood pressure of conscious rats through renin-angiotensin system (RAS).
Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Captopril; Hypotension; Hypoxia; Male; Oligopeptides; Rats, Wistar; Renin-Angiotensin System; Salivary Proteins and Peptides; Tetrazoles; Valine; Valsartan | 2014 |
Simultaneous Use of Intravenous Lipid Emulsion and Plasma Exchange Therapies in Multiple Drug Toxicity.
Topics: Amisulpride; Antihypertensive Agents; Antipsychotic Agents; Aripiprazole; Diazepam; Drug-Related Side Effects and Adverse Reactions; Fat Emulsions, Intravenous; Female; Humans; Hypnotics and Sedatives; Hypotension; Middle Aged; Paliperidone Palmitate; Plasma Exchange; Suicide, Attempted; Sulpiride; Treatment Outcome; Turkey; Valsartan | 2016 |
Sacubitril/Valsartan (Entresto) for Heart Failure.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Heart Failure; Humans; Hyperkalemia; Hypotension; Neprilysin; Renal Insufficiency; Severity of Illness Index; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2016 |
Sacubitril/valsartan and low blood pressure in heart failure with reduced ejection fraction.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypotension; Stroke Volume; Tetrazoles; Valsartan | 2017 |
Prolonged severe hypotension following combined amlodipine and valsartan ingestion.
Topics: Aged; Amlodipine; Antidotes; Antihypertensive Agents; Blood Glucose; Calcium Channel Blockers; Cardiac Catheterization; Drug Interactions; Drug Overdose; Female; Glucagon; Humans; Hypotension; Insulin; Naloxone; Severity of Illness Index; Suicide, Attempted; Tetrazoles; Time Factors; Valine; Valsartan | 2008 |
Angiotensin-receptor-blocker-induced refractory hypotension responds to methylene blue.
Topics: Aged; Angiotensin Receptor Antagonists; Carbazoles; Carvedilol; Citalopram; Crystalloid Solutions; Diabetes Mellitus, Type 2; Drug Resistance; Female; Gastric Bypass; Humans; Hypotension; Isotonic Solutions; Obesity, Morbid; Phenylephrine; Preoperative Care; Propanolamines; Tetrazoles; Valine; Valsartan | 2012 |
Valsartan, captopril, or both in myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Humans; Hypotension; Myocardial Infarction; Tetrazoles; Valine; Valsartan | 2004 |
Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats.
Topics: Animals; Antihypertensive Agents; Hypotension; Microdialysis; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Vasodilation | 2000 |
Angiotensin type 2 receptor-mediated hypotension in angiotensin type-1 receptor-blocked rats.
Topics: Angiotensin Receptor Antagonists; Animals; Blood Pressure Determination; Diet, Sodium-Restricted; Hypotension; Losartan; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Oligopeptides; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan; Vasodilation | 2001 |
Valsartan in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Therapy, Combination; Heart Failure; Humans; Hypotension; Tetrazoles; Valine; Valsartan | 2002 |